Anixa Australian Patent Breast Cancer Vaccine
Analysis based on 6 articles · First reported Sep 21, 2026 · Last updated Sep 21, 2026
The patent grant modestly strengthens Anixa's intellectual property position and long-term commercialization optionality for its breast cancer vaccine, but it does not change near-term revenue or clinical timelines, so the market reaction was muted with the stock slightly lower. For the broader biotech sector the news is immaterial, as it concerns a single clinical-stage company's IP estate rather than a sector-wide development.
Anixa Biosciences announced that Australia — Australian Government issued Patent Number 2020221280, a composition-of-matter patent titled Vaccine Adjuvants and Formulations, covering its breast cancer vaccine technology in Australia through 2040. The technology is exclusively licensed from Cleveland Clinic, where it was developed, and the co-inventors are Dr. Ron Johnson and the late Dr. Vincent Tuohy. The Australian patent complements Anixa's existing patent estate in the United States, Europe, China, and Japan, strengthening its global intellectual property position and its ability to pursue regulatory approvals, partnerships, and commercialization. The vaccine targets human alpha-lactalbumin, a retired protein aberrantly expressed in certain breast cancers, aiming to prime the immune system against tumor formation, particularly in aggressive forms such as triple-negative breast cancer. A recently completed Phase 1 trial at Cleveland Clinic, funded by the United States — United States Department of Defense, met all major primary endpoints, was safe and well tolerated, and generated protocol-defined immune responses in more than 74% of participants. No preventive breast cancer vaccine is currently approved anywhere in the world. Anixa's broader pipeline includes liraltagene autoleucel, an ovarian cancer immunotherapy developed with H. Lee Moffitt Cancer Center & Research Institute. Cleveland Clinic is entitled to royalties and other commercialization revenues under the exclusive license. Anixa shares traded down about 2 percent following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard